Research in sepsis and acute respiratory distress syndrome: Are we changing course?

Critical Care Medicine

Volumn 27, Issue 2, 1999, Pages 434-436

  Bernard, Gordon R ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Clinical trials; Sepsis; Sepsis syndrome

Indexed keywords

ANTIINFLAMMATORY AGENT; CENTOXIN; CORTICOSTEROID; ENDOTOXIN ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT RESPIRATORY DISTRESS SYNDROME; CASE FINDING; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; INTENSIVE CARE; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SAMPLE; SEPSIS; STANDARDIZATION; STATISTICAL ANALYSIS;

EID: 0032965070     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199902000-00057     Document Type: Review

References (16)

1. 1. Fuhrman BP, Abraham E, Dellinger RP: Futility of randomized, controlled ARDS trials - A new approach is needed. Crit Care Med 1999; 27:431-433
2. 2. Nasraway SA Jr: Sepsis research: We must change course. Crit Care Med 1999; 27:427-430
3. 3. Bone RC, Balk RA, Cerra FB, et al: American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definition of sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
4. 4. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA1-A human monoclonal antibody against endotoxin: A randomized, double blind, placebo-controlled trial. N Engl J Med 1991;324:429-436
5. 5. The National Committee for the Evaluation of Centoxin. The French National registry of HA-1A (Centoxin) in septic shock: A cohort study of 600 patients. Arch Intern Med 1994;154:2484-2491
6. 6. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of murine monoclonal IGM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266: 1097-1102
7. 7. Quezado ZM, Natanson C, Alling DW, et al: A controlled trial of HA-1A in a canine model of Gram-negative septic shock. JAMA 1993; 269:2221-2227
8. 8. Wheeler AP, Hardie WD, Bernard G: Studies of an antiendotoxin antibody in preventing the physiologic changes of endotoxemia in awake sheep. Am Rev Respir Dis 1990; 142:775-781
9. 9. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European Consensus Conference on Acute Respiratory Distress Syndrome (Part I): Definitions, mechanisms, relevant outcomes, and clinical trial coordination. J Crit Care 1994; 9:72-81
10. 10. Dellinger , RP, Zimmerman, JL, Taylor RW et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome. Crit Care Med 1998; 26:15-23
11. 11. Bernard GR, Wheeler AP, Russell JA, et al: Effects of Ibuprofen on the physiology, lactic acidosis and survival of sepsis syndrome. N Engl J Med 1997; 336:912-918
12. 12. Amato MBP, Barba CSV, Medeiros DM, et al: Beneficial effects of the "open lung approach" with low distending pressures in acute respiratory distress syndrome: A prospective randomized study on mechanical ventilation. Am J Respir Crit Care Med 1995; 152: 1835-1846
13. 13. Bernard GR: The Brussel's score. Sepsis 1997; 1:43
14. 14. Bernard, GR: Quantification of organ dysfunction: Seeking standardization. Crit Care Med 1998; 26:1767-1768
15. 15. Cronin L, Cook DJ, Carlet J, et al: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439
16. 16. Natanson C, Hoffman WD, Suffredini AF, et al: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120:771-783